PepGen Inc. (PEPG): R&D Expense
$71.04M
Year ended 2025-12-31
$52.80M
Trailing 12 months to 2026-06-30
+9.5%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.04M | -7.1% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $76.48M | +12.3% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $68.13M | +26.0% | 2025-02-24, From 2023-01-01 |
| 2022-12-31 | $54.08M | +184.6% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $19.00M | n/a | 2023-03-23, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| PepGen Inc. (PEPG) | 2025-12-31 | $71.04M | -7.1% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $66.27M | +27.5% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $70.09M | +117.5% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $46.71M | +225.8% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $23.39M | +27.6% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $1.63M | n/a |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $45.62M | -2.9% |
Compare PEPG, GOSS, ELDN, CRBP side by side · Screen every company in Pharmaceutical Preparations ↗